

## Case Report

# *De novo* CD5-positive Diffuse Large B-cell Lymphoma Presenting with Leg Edema

Huai-Hsuan Huang<sup>1</sup>, Chung-Wu Lin<sup>2</sup>, Sung-Hsin Kuo<sup>1,3,4\*</sup>, Ann-Lii Cheng<sup>1,3,4</sup>

<sup>1</sup>Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

<sup>2</sup>Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

<sup>3</sup>Department of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

<sup>4</sup>Cancer Research Center, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

### Abstract.

**Background:** Diffuse large B-cell lymphoma (DLBCL) is the most common of all non-Hodgkin's lymphomas, and is also a heterogeneous disease.

**Case Description:** Here, we report a case of *de novo* CD5-positive DLBCL of the right iliac, right inguinal, and right femoral with retroperitoneal and peri-esophageal involvement who was diagnosed not only by flow cytometric immunophenotyping but also by immunohistochemistry analyses. Initially, the patient presented with a complaint of progressive right leg edema for 5 months. Although complete remission was achieved after three cycles of immunochemotherapy (rituximab plus CEOP), relapse with a massive right side pleural effusion developed four months later, after a total of six cycles of immunochemotherapy were administered. We also reviewed the clinical manifestations and treatments for the disease, and highlighted the importance of identifying *de novo* CD5-positive DLBCL from other DLBCL, and of developing proper treatment strategies for this subgroup of patients.

**Conclusions:** In conclusion, *de novo* CD5-positive DLBCL is a distinct group of DLBCL with aggressive courses of disease progress, with typically worse prognosis than DLBCL.

**Keywords :** diffuse large B-cell lymphoma, CD5-positive, rituximab

## 病例報告

# 以腳部水腫來表現之原發性 CD5 陽性瀰漫性大 B 細胞淋巴瘤

黃懷萱<sup>1</sup> 林中梧<sup>2</sup> 郭頌鑫<sup>1,3,4\*</sup> 鄭安理<sup>1,3,4</sup>

<sup>1</sup> 國立台灣大學附設醫院 內科部

<sup>2</sup> 國立台灣大學附設醫院 病理部

<sup>3</sup> 國立台灣大學附設醫院 腫瘤醫學部

<sup>4</sup> 國立台灣大學附設醫院 癌症研究中心